Syndicated Research Studies

Oligonucleotide Synthesis Market Summary The global oligonucleotide synthesis market size was valued at USD 4.05 billion in 2024 and is expected to reach USD 8.83 billion by 2030, expanding at a CAGR of 13.2% from 2025 to 2030. Growth in the nucleic acid isolation and purification (NAIP) segment is driven by increasing adoption of sequencing platforms for clinical diagnostics, rising genomics and enzymology research activities, and a steady increase in R&D investments. Oligonucleotide therapeutics continue to show strong potential in the treatment of chronic diseases, including cardiovascular conditions, cancers, and retinal disorders. Expanding applications of oligo sequences across diverse biotechnology domains further support market growth. The rising need for molecular diagnostics within precision medicine represents a significant emerging opportunity for the oligonucleotide synthesis industry. Technological advancements—such as CRISPR, high-throughput sequencing, and ...

Oligonucleotide Synthesis Market Growth & Trends The global oligonucleotide synthesis market size is projected to reach USD 8.53 billion by 2030, registering a CAGR of 13.21% from 2024 to 2030, according to a new report by Grand View Research, Inc. The strong pipeline of oligonucleotide therapeutics in clinical trials, advancements in gene editing technologies, and increasing R&D spending by biotechnology companies are some of the major factors driving the market growth. Oligonucleotide therapeutics participants are present in the late stages of clinical trials and are expected to be approved & commercialized over the forecast period. Companies have increased investments to develop oligonucleotide-based therapeutics. In October 2023, GSK plc and Arrowhead Pharmaceuticals announced a contract with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to assign GSK exclusive worldwide rights to develop and commercialize JNJ-3989. Janssen in...